Prokineticin 2 and Prokineticin Receptor 2 as a Target to Treat Epilepsy and Seizures

Background: PK2 belongs to a family of secreted peptides that regulate diverse biological functions including serving as a regulatory molecule for circadian rhythms. The signaling of PK2 is mediated through two cognate G-protein coupled receptors Prokineticin Receptor 1 and Prokineticin Receptor 2 (PKR1 and PKR2). Technology: Researchers at the University of California have found that PK2 is an important regulator of seizure onset and epilepsy. A PKR2 modulator would thus help treat epileptic patients and/or patients suffering from non-epileptic seizures. Certain materials such as cDNAs and cell lines that may be used as screening and research tools are readily available for licensing. This technology is also available for sponsor research opportunities.

Type of Offer: Licensing

Next Patent »
« More Biotech Patents
« More Pharmaceutical Patents

Share on      

CrowdSell Your Patent